Wojciech Olszewski

Wojciech Olszewski

Auto-generated profile, based on publicly available information

Wojciech Olszewski

Department of Pathology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
GVGiuseppe Viale
Giuseppe Viale
AGAnita Giobbie-Hurder
Anita Giobbie-Hurder
MRMeredith M. Regan
Meredith M. Regan
ACAlan S. Coates
Alan S. Coates
Mauro MastropasquaMauro Mastropasqua
Mauro Mastropasqua
AGAron Goldhirsch
Aron Goldhirsch
Purpose: To evaluate the prognostic and predictive value of Ki-67 labeling index (LI) in a trial comparing letrozole (Let) with tamoxifen (Tam) as adjuvant therapy in postmenopausal women with early breast cancer.Patients and Methods: Breast International Group (BIG) trial 1-98 randomly assigned 8,010 patients to four treatment arms comparing Let and Tam with sequences of each agent. Of 4,922 patients randomly assigned to receive 5 years of monotherapy with either agent, 2,685 had primary tumor material available for central pathology assessment of Ki-67 LI by immunohistochemistry and had tumors confirmed to express estrogen receptors after central review. The prognostic and predictive value of centrally measured Ki-67 LI on disease-free survival (DFS) were assessed among these patients using proportional hazards modeling, with Ki-67 LI values dichotomized at the median value of 11%.Results: Higher values of Ki-67 LI were associated with adverse prognostic factors and with worse DFS (hazard ratio [HR; high:low] = 1.8; 95% CI, 1.4 to 2.3). The magnitude of the treatment benefit for Let versus Tam was greater among patients with high tumor Ki-67 LI (HR [Let:Tam] = 0.53; 95% CI, 0.39 to 0.72) than among patients with low tumor Ki-67 LI (HR [Let:Tam] = 0.81; 95% CI, 0.57 to 1.15; interaction P = .09).Conclusion: Ki-67 LI is confirmed as a prognostic factor in this study. High Ki-67 LI levels may identify a patient group that particularly benefits from initial Let adjuvant therapy.

27 April 2016 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
FCfor the Polish Brain Metastasis Consortium
for the Polish Brain Metastasis Consortium
RDRENATA DUCHNOWSKA
RENATA DUCHNOWSKA
RPRafał Pęksa
Rafał Pęksa
BRBarbara Radecka
Barbara Radecka
TMTomasz S. Mandat
Tomasz S. Mandat
JJJacek Jassem
Jacek Jassem
A better understanding of immune response in breast cancer brain metastases (BCBM) may prompt new preventive and therapeutic strategies. Immunohistochemical expression of stromal tumor-infiltrating lymphocytes (TILs: CD4, CD8, CTLA4), macrophage/microglial cells (CD68), programmed cell death protein 1 receptor (PD-1), programmed cell death protein 1 receptor ligand (PD-L)1, PD-L2 and glial fibrillary acid protein was assessed in 84 BCBM and their microenvironment. Median survival after BCBM excision was 18.3 months (range 0–99). Median number of CD4+, CD8+ TILs and CD68+ was 49, 69 and 76 per 1 mm2, respectively. PD-L1 and PD-L2 expression in BCBM was present in 53 % and 36 % of cases, and was not related to BCBM phenotype. PD-1 expression on TILs correlated positively with CD4+ and CD8+ TILs (r = 0.26 and 0.33), and so did CD68+ (r = 0.23 and 0.27, respectively). In the multivariate analysis, survival after BCBM excision positively correlated with PD-1 expression on TILs (hazard ratio (HR) = 0.3, P = 0.003), CD68+ infiltration (HR = 0.2, P < 0.001), brain radiotherapy (HR = 0.1, P < 0.001), endocrine therapy (HR = 0.1, P < 0.001), and negatively with hormone-receptor-negative/human epidermal growth factor receptor 2 (HER2)-positive phenotype of primary tumor (HR = 2.6, P = 0.01), HER2 expression in BCBM (HR = 4.9, P = 0.01). PD-L1 and PD-L2 expression is a common occurrence in BCBM, irrespective of primary tumor and BCBM phenotype. Favorable prognostic impact of PD-1 expression on TILs suggests a beneficial effect of preexisting immunity and implies a potential therapeutic role of immune checkpoint inhibitors in BCBM.

16 August 2012 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
RDRENATA DUCHNOWSKA
RENATA DUCHNOWSKA
RDRafal Dziadziuszko
Rafal Dziadziuszko
TTTomasz Trojanowski
Tomasz Trojanowski
TMTomasz S. Mandat
Tomasz S. Mandat
WOWaldemar Och
Waldemar Och
TCthe Polish Brain Metastasis Consortium
the Polish Brain Metastasis Consortium
Introduction: We investigated the status of estrogen receptor alpha (ERα), progesterone receptor (PR), and epidermal growth factor receptor 2 (HER2) in primary tumor and in the corresponding brain metastases in a consecutive series of breast cancer patients. Additionally, we studied factors potentially influencing conversion and evaluated its association with survival. Methods: The study group included 120 breast cancer patients. ERα, PR, and HER2 status in primary tumors and in matched brain metastases was determined centrally by immunohistochemistry and/or fluorescence in situ hybridization. Results: Using the Allred score of ≥ 3 as a threshold, conversion of ERα and PR in brain metastases occurred in 29% of cases for both receptors, mostly from positive to negative. Conversion of HER2 occurred in 14% of patients and was more balanced either way. Time to brain relapse and the use of chemotherapy or trastuzumab did not influence conversion, whereas endocrine therapy induced conversion of ERα (P = 0.021) and PR (P = 0.001), mainly towards their loss. Receptor conversion had no significant impact on survival. Conclusions: Receptor conversion, particularly loss of hormone receptors, is a common event in brain metastases from breast cancer, and endocrine therapy may increase its incidence. Receptor conversion does not significantly affect survival.

16 June 2011 in Pathology and Oncology Research
Verified
Journal Article
Open access
PDF file
ASAleksandra Stanczak
Aleksandra Stanczak
RSRafał Stec
Rafał Stec
LBLubomir Bodnar
Lubomir Bodnar
WOWojciech Olszewski
Wojciech Olszewski
MCMarzena Cichowicz
Marzena Cichowicz
MLMonika Lamparska-Przybysz
Monika Lamparska-Przybysz
Wnt/β-catenin pathway plays an important role in initiation and progression of colorectal oncogenesis. The aim of this study was to determine expression and localization of E-cadherin, β-catenin and Wnt-1 proteins in colorectal tumors. Expression of β-catenin, E-cadherin and Wnt-1 was determined by immunohistochemistry on advanced colorectal cancers. Abnormal expression of E-cadherin, β-catenin, Wnt-1 was observed. Additionally, we revealed correlations between levels of studied proteins and histoclinical data. In multivariate analysis nuclear β-catenin, higher carcinoembryonic antigen serum level before treatment, female sex and tumor localized in colon or rectum were independent unfavorable prognostic factors. These findings support the hypothesis that Wnt/β-catenin pathway plays an important role in advanced colorectal carcinoma.

28 July 2007 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
AZAnna Zaczek
Anna Zaczek
MWMarzena Wełnicka-Jaśkiewicz
Marzena Wełnicka-Jaśkiewicz
KBKrzysztof Piotr Bielawski
Krzysztof Piotr Bielawski
JJJanusz Jaśkiewicz
Janusz Jaśkiewicz
ABAndrzej Badzio
Andrzej Badzio
JJJacek Jassem
Jacek Jassem

7 August 2012 in The Oncologist
Verified
Journal Article
Open access
PDF file
AZAnna Zaczek
Anna Zaczek
AMAleksandra Markiewicz
Aleksandra Markiewicz
BSBarbara Seroczyńska
Barbara Seroczyńska
Jaroslaw SkokowskiJaroslaw Skokowski
Jaroslaw Skokowski
JJJanusz Jaśkiewicz
Janusz Jaśkiewicz
JJJacek Jassem
Jacek Jassem
Learning Objectives: After completing this course, the reader will be able to: Describe the prognostic role of TOP2A gene dosage determined by quantitative PCR in HER-2-negative breast cancer.Describe the relationship between HER-2 status and TOP2A status in breast cancer tumors.Gain greater understanding of methods used for TOP2A status determination, including the advantages of quantitative PCR. CME This article is available for continuing medical education credit at CME.TheOncologist.com Background.: Previous studies showed the prognostic and predictive impact of human epidermal growth factor receptor 2 (HER-2) gene alterations analyzed separately and jointly with topoisomerase II α (TOP2A) gene alterations; however, the role of TOP2A gene abnormalities alone has not been thoroughly investigated. Additionally, TOP2A aberrations were typically studied in HER-2-positive (HER-2+) tumors because these genes are frequently coamplified. Therefore, the knowledge concerning the impact of TOP2A abnormalities in HER-2-negative (HER-2−) patients is scarce. This study aimed to investigate the clinical significance of TOP2A anomalies in breast cancer patients with HER-2− and HER-2+ tumors. Materials and Methods.: Snap-frozen tumor samples from 322 consecutive stage I–III breast cancer patients were analyzed for TOP2A gene dosage using quantitative real-time PCR (qPCR). Results.: A high TOP2A gene dosage was found in 94 tumors (29%)—32% and 27% of HER-2+ and HER-2− tumors, respectively. The mean TOP2A gene dosages in the HER-2+ and HER-2− groups were 1.49 ± 1.03 and 1.09 ± 0.35, respectively. High TOP2A gene dosage had an inverse prognostic impact in terms of shorter disease-free survival (DFS) and overall survival (OS) times in the entire group and in both the HER-2− and HER-2+ subgroups. The unfavorable prognostic impact of TOP2A gene dosage was maintained in the multivariate Cox regression analysis in the entire group and in HER-2− patients. Conclusions.: A high gene dosage of TOP2A determined using qPCR occurs frequently both in HER-2+ and HER-2− tumors and has a strong adverse prognostic impact.